Cornerstone Wealth Group’s Moderna MRNA Stock Holding History

Cornerstone Wealth Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$242K	Buy	+1,259	New	+$136K	0.01%	449

Other funds holding MRNA

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Cornerstone Wealth Group's MRNA Position: Q3 2026 in Review

Cornerstone Wealth Group opened a new position in Moderna (MRNA) in Q3 2026: 1,259 shares worth $242K. The stake represents 0.01% of the portfolio and ranks #449 among its holdings.

477 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Cornerstone Wealth Group held 1,259 shares of Moderna worth $242K as of Q3 2026.
Moderna was a new Cornerstone Wealth Group position in Q3 2026.
Moderna made up 0.01% of Cornerstone Wealth Group's portfolio in Q3 2026, its #449 holding.
477 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Cornerstone Wealth Group's 13F filing for Q3 2026, filed 2 Nov 2026.